The lack of induction of TβRII expression in prostate cancer cells by doxazosin is consistent with our earlier report indicating no changes in TβRII protein levels in prostate tissue (from BPH patients) after treatment with the quinazolines (Glassman et al, 2001). The gene discussed is TGFBR2; the disease is benign prostatic hyperplasia.